(NHI) National Health Investors - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US63633D1046
Stock: Senior Housing, Assisted Living, Memory Care, Skilled Nursing
Total Rating 45
Risk 79
Buy Signal -0.27
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.86% |
| Yield on Cost 5y | 7.17% |
| Yield CAGR 5y | -1.09% |
| Payout Consistency | 94.0% |
| Payout Ratio | 1.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.4% |
| Relative Tail Risk | 0.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.17 |
| Alpha | 22.36 |
| Character TTM | |
|---|---|
| Beta | 0.177 |
| Beta Downside | 0.081 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.87% |
| CAGR/Max DD | 0.96 |
Description: NHI National Health Investors January 12, 2026
National Health Investors, Inc. (NYSE: NHI) is a self-managed REIT founded in 1991 that focuses on senior-housing and medical-facility assets through sale-leaseback, joint-venture, mortgage and mezzanine financing structures. Its portfolio spans independent living, assisted living, memory-care, entrance-fee retirement communities, senior-living campuses, skilled-nursing facilities and specialty hospitals.
Key metrics to watch include its 2023 occupancy rate of roughly 92 % across senior-housing properties, a FY 2023 adjusted funds-from-operations (AFFO) growth of 6 % YoY, and a dividend yield near 5.8 % with a payout ratio of about 85 % of AFFO. The sector is driven by macro trends such as the U.S. aging population (≈10 % of households now include a senior), rising demand for memory-care beds, and the sensitivity of REIT financing costs to the Federal Reserve’s interest-rate policy.
For a deeper, data-rich perspective on NHI’s valuation and risk profile, you may find ValueRay’s analyst tools useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 147.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.14 > 1.0 |
| NWC/Revenue: 55.88% < 20% (prev -11.65%; Δ 67.53% < -1%) |
| CFO/TA 0.08 > 3% & CFO 228.0m > Net Income 147.3m |
| Net Debt (1.03b) to EBITDA (278.3m): 3.69 < 3 |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.6m) vs 12m ago 8.27% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 13.81% > 50% (prev 13.37%; Δ 0.44% > 0%) |
| Interest Coverage Ratio: 3.61 > 6 (EBITDA TTM 278.3m / Interest Expense TTM 55.5m) |
Altman Z'' 6.68
| A: 0.07 (Total Current Assets 381.2m - Total Current Liabilities 182.5m) / Total Assets 2.69b |
| B: 1.01 (Retained Earnings 2.71b / Total Assets 2.69b) |
| C: 0.08 (EBIT TTM 200.3m / Avg Total Assets 2.58b) |
| D: 2.27 (Book Value of Equity 2.71b / Total Liabilities 1.19b) |
| Altman-Z'' Score: 6.68 = AAA |
Beneish M -4.00
| DSRI: 0.83 (Receivables 299.6m/333.6m, Revenue 355.6m/328.9m) |
| GMI: 1.00 (GM 96.83% / 96.63%) |
| AQI: -1.40 (AQ_t 0.00 / AQ_t-1 -0.00) |
| SGI: 1.08 (Revenue 355.6m / 328.9m) |
| TATA: -0.03 (NI 147.3m - CFO 228.0m) / TA 2.69b) |
| Beneish M-Score: -4.56 (Cap -4..+1) = AAA |
What is the price of NHI shares?
As of February 08, 2026, the stock is trading at USD 84.07 with a total of 170,428 shares traded.
Over the past week, the price has changed by +2.37%, over one month by +10.10%, over three months by +12.97% and over the past year by +28.30%.
Over the past week, the price has changed by +2.37%, over one month by +10.10%, over three months by +12.97% and over the past year by +28.30%.
Is NHI a buy, sell or hold?
National Health Investors has received a consensus analysts rating of 3.88.
Therefore, it is recommended to buy NHI.
- StrongBuy: 3
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NHI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85.6 | 1.9% |
| Analysts Target Price | 85.6 | 1.9% |
| ValueRay Target Price | 100.9 | 20% |
NHI Fundamental Data Overview February 03, 2026
P/E Trailing = 25.3457
P/E Forward = 12.837
P/S = 10.9407
P/B = 2.5983
P/EG = 1.99
Revenue TTM = 355.6m USD
EBIT TTM = 200.3m USD
EBITDA TTM = 278.3m USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 100.0m USD (from shortTermDebt, last quarter)
Debt = 1.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.03b USD (from netDebt column, last quarter)
Enterprise Value = 4.94b USD (3.91b + Debt 1.11b - CCE 81.6m)
Interest Coverage Ratio = 3.61 (Ebit TTM 200.3m / Interest Expense TTM 55.5m)
EV/FCF = 22.47x (Enterprise Value 4.94b / FCF TTM 219.8m)
FCF Yield = 4.45% (FCF TTM 219.8m / Enterprise Value 4.94b)
FCF Margin = 61.82% (FCF TTM 219.8m / Revenue TTM 355.6m)
Net Margin = 41.42% (Net Income TTM 147.3m / Revenue TTM 355.6m)
Gross Margin = unknown ((Revenue TTM 355.6m - Cost of Revenue TTM 11.3m) / Revenue TTM)
Tobins Q-Ratio = 1.84 (Enterprise Value 4.94b / Total Assets 2.69b)
Interest Expense / Debt = 1.18% (Interest Expense 13.1m / Debt 1.11b)
Taxrate = 21.0% (US default 21%)
NOPAT = 158.2m (EBIT 200.3m * (1 - 21.00%))
Current Ratio = 2.09 (Total Current Assets 381.2m / Total Current Liabilities 182.5m)
Debt / Equity = 0.75 (Debt 1.11b / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = 3.69 (Net Debt 1.03b / EBITDA 278.3m)
Debt / FCF = 4.67 (Net Debt 1.03b / FCF TTM 219.8m)
Total Stockholder Equity = 1.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.72% (Net Income 147.3m / Total Assets 2.69b)
RoE = 10.24% (Net Income TTM 147.3m / Total Stockholder Equity 1.44b)
RoCE = 8.18% (EBIT 200.3m / Capital Employed (Equity 1.44b + L.T.Debt 1.01b))
RoIC = 6.09% (NOPAT 158.2m / Invested Capital 2.60b)
WACC = 5.33% (E(3.91b)/V(5.02b) * Re(6.57%) + D(1.11b)/V(5.02b) * Rd(1.18%) * (1-Tc(0.21)))
Discount Rate = 6.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 4.77%
[DCF Debug] Terminal Value 86.97% ; FCFF base≈210.9m ; Y1≈225.3m ; Y5≈272.2m
Fair Price DCF = 147.7 (EV 8.06b - Net Debt 1.03b = Equity 7.03b / Shares 47.6m; r=5.90% [WACC]; 5y FCF grow 7.63% → 2.90% )
EPS Correlation: 13.34 | EPS CAGR: -28.31% | SUE: -4.0 | # QB: 0
Revenue Correlation: 86.39 | Revenue CAGR: 7.02% | SUE: 1.22 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.77 | Chg30d=-0.019 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=3.35 | Chg30d=-0.022 | Revisions Net=-1 | Growth EPS=+12.0% | Growth Revenue=+15.3%
P/E Forward = 12.837
P/S = 10.9407
P/B = 2.5983
P/EG = 1.99
Revenue TTM = 355.6m USD
EBIT TTM = 200.3m USD
EBITDA TTM = 278.3m USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 100.0m USD (from shortTermDebt, last quarter)
Debt = 1.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.03b USD (from netDebt column, last quarter)
Enterprise Value = 4.94b USD (3.91b + Debt 1.11b - CCE 81.6m)
Interest Coverage Ratio = 3.61 (Ebit TTM 200.3m / Interest Expense TTM 55.5m)
EV/FCF = 22.47x (Enterprise Value 4.94b / FCF TTM 219.8m)
FCF Yield = 4.45% (FCF TTM 219.8m / Enterprise Value 4.94b)
FCF Margin = 61.82% (FCF TTM 219.8m / Revenue TTM 355.6m)
Net Margin = 41.42% (Net Income TTM 147.3m / Revenue TTM 355.6m)
Gross Margin = unknown ((Revenue TTM 355.6m - Cost of Revenue TTM 11.3m) / Revenue TTM)
Tobins Q-Ratio = 1.84 (Enterprise Value 4.94b / Total Assets 2.69b)
Interest Expense / Debt = 1.18% (Interest Expense 13.1m / Debt 1.11b)
Taxrate = 21.0% (US default 21%)
NOPAT = 158.2m (EBIT 200.3m * (1 - 21.00%))
Current Ratio = 2.09 (Total Current Assets 381.2m / Total Current Liabilities 182.5m)
Debt / Equity = 0.75 (Debt 1.11b / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = 3.69 (Net Debt 1.03b / EBITDA 278.3m)
Debt / FCF = 4.67 (Net Debt 1.03b / FCF TTM 219.8m)
Total Stockholder Equity = 1.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.72% (Net Income 147.3m / Total Assets 2.69b)
RoE = 10.24% (Net Income TTM 147.3m / Total Stockholder Equity 1.44b)
RoCE = 8.18% (EBIT 200.3m / Capital Employed (Equity 1.44b + L.T.Debt 1.01b))
RoIC = 6.09% (NOPAT 158.2m / Invested Capital 2.60b)
WACC = 5.33% (E(3.91b)/V(5.02b) * Re(6.57%) + D(1.11b)/V(5.02b) * Rd(1.18%) * (1-Tc(0.21)))
Discount Rate = 6.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 4.77%
[DCF Debug] Terminal Value 86.97% ; FCFF base≈210.9m ; Y1≈225.3m ; Y5≈272.2m
Fair Price DCF = 147.7 (EV 8.06b - Net Debt 1.03b = Equity 7.03b / Shares 47.6m; r=5.90% [WACC]; 5y FCF grow 7.63% → 2.90% )
EPS Correlation: 13.34 | EPS CAGR: -28.31% | SUE: -4.0 | # QB: 0
Revenue Correlation: 86.39 | Revenue CAGR: 7.02% | SUE: 1.22 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.77 | Chg30d=-0.019 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=3.35 | Chg30d=-0.022 | Revisions Net=-1 | Growth EPS=+12.0% | Growth Revenue=+15.3%